KemPharm competitors

KemPharm's competitors include Adaptive Biotechnologies, F-star Biotechnology, Spring Bank Pharmaceuticals and WaferGen Biosystems
Add company...
KemPharm
KemPharm is a biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases.
Adaptive Biotechnologies
Adaptive Biotechnologies offers research and diagnostic tools for scientists and clinicians involved in genomic immunology.
F-star Biotechnology
F-star is developing a pipeline of novel bispecific antibodies with a therapeutic focus in immuno-oncology and oncology.
Spring Bank Pharmaceuticals
Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform.
WaferGen Biosystems
Innovative single-cell analysis and clinical research solutions.
Founding Date
Founding Date
2006
Founding Date
2009
Founding Date
2006
Founding Date
2002
Founding Date
2003
Type
Type
Public
Type
Private
Type
Private
Type
Public
Type
Subsidiary
Tags
Locations
Locations
Kissimmee, US HQ
Locations
Seattle, US HQ
South San Francisco, US
Locations
Cambridgeshire, GB HQ
Wien, AT
Locations
Hopkinton, US HQ
Milford, US
Locations
Fremont, US HQ
Luxembourg, LU
Employees
Employees
32
Employees
2642% increase
Employees
831% decrease
Employees
15
Employees
N/A
Valuation ($)
Valuation ($)
75 m
Valuation ($)
1.1 b
Valuation ($)
N/A
Valuation ($)
156.9 m
Valuation ($)
N/A
Facebook likes
Facebook likes
N/A
Facebook likes
534
Facebook likes
N/A
Facebook likes
5.3 k
Facebook likes
627
Twitter followers
Twitter followers
61
Twitter followers
2.3 k
Twitter followers
486
Twitter followers
1.2 k
Twitter followers
294

Financial

Net income
Net income
($16.5m) (FY, 2016)
Net income
N/A
Net income
(£1.5m) (FY, 2017)
Net income
($17.4m) (FY, 2016)
Net income
N/A

Funding

Latest funding round
Latest funding round
N/A
Latest funding round
$ 206.2m (over 3 years ago)
Latest funding round
$ 9.4m (almost 5 years ago)
Latest funding round
N/A
Latest funding round
N/A
Total funding raised
Total funding raised
N/A
Total funding raised
$ 539m
Total funding raised
$ 57.3m
Total funding raised
$ 14.4m
Total funding raised
$ 56.9m
For sources of this data, please see the company profileDownload Excel

View company profiles

Adaptive Biotechnologies
HQ
Seattle, US
Employees
264↑ 2% increase

Adaptive Biotechnologies offers research and diagnostic tools for scientists and clinicians involved in genomic immunology.

View company
F-star Biotechnology
HQ
Cambridgeshire, GB
Employees
83↓ 1% decrease

F-star is developing a pipeline of novel bispecific antibodies with a therapeutic focus in immuno-oncology and oncology.

View company
Spring Bank Pharmaceuticals
HQ
Hopkinton, US
Employees
15

Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform.

View company
WaferGen Biosystems
HQ
Fremont, US

Innovative single-cell analysis and clinical research solutions.

View company